康复新液联合泮托拉唑治疗消化性溃疡疗效分析
|
摘要
目的探讨康复新液联合泮托拉唑治疗消化性溃疡的临床效果,以期提高患者的生活质量。方法随机将我院2016年5月—2017年5月收治的72例消化性溃疡患者分为两组,每组36例。对照组行泮托拉唑+克拉霉素+阿莫西林三联疗法,观察组在对照组的基础上行康复新液治疗。比较两组临床疗效。结果观察组总有效率、愈合时间、不良反应发生率及1年复发率分别为94.44%、(12.21±1.54)d、2.78%(1/36)、2.78%(1/36);对照组分别为69.44%、(29.47±1.86)d、22.22%(8/36)、25.0%(9/36);两组比较差异显著(P <0.05)。结论康复新液联合泮托拉唑治疗消化性溃疡效果理想,值得推广应用。
Objective To investigate the clinical effect of Kangfuxin liquid combined with pantoprazole in the treatment of peptic ulcer, in order to improve the quality of life of patients. Methods 72 patients with peptic ulcer admitted to our hospital from May 2016 to May 2017 were randomly divided into two groups, 36 cases in each group. The control group received pantoprazole + clarithromycin + amoxicillin triple therapy, and the observation group was treated with the Kangfuxin liquid on the basis of control group. The clinical efficacy of the two groups was compared. Results The total effective rate, healing time, adverse reaction rate and 1-year recurrence rate of the observation group were 94.44%,(12.21±1.54) d, 2.78%(1/36), and 2.78%(1/36), respectively.The control group were 69.44%,(29.47±1.86) d, 22.22%(8/36)、25.0%(9/36); The difference between the two groups was significant(P <0.05).Conclusion Kangfuxin liquid combined with pantoprazole is effective in treating peptic ulcer, and is worthy of popularization and application.
Objective To investigate the clinical effect of Kangfuxin liquid combined with pantoprazole in the treatment of peptic ulcer, in order to improve the quality of life of patients. Methods 72 patients with peptic ulcer admitted to our hospital from May 2016 to May 2017 were randomly divided into two groups, 36 cases in each group. The control group received pantoprazole + clarithromycin + amoxicillin triple therapy, and the observation group was treated with the Kangfuxin liquid on the basis of control group. The clinical efficacy of the two groups was compared. Results The total effective rate, healing time, adverse reaction rate and 1-year recurrence rate of the observation group were 94.44%,(12.21±1.54) d, 2.78%(1/36), and 2.78%(1/36), respectively.The control group were 69.44%,(29.47±1.86) d, 22.22%(8/36)、25.0%(9/36); The difference between the two groups was significant(P <0.05).Conclusion Kangfuxin liquid combined with pantoprazole is effective in treating peptic ulcer, and is worthy of popularization and application.
引文
[1]卓越.康复新液治疗难治性消化性溃疡50例临床观察[J].深圳中西医结合杂志,2015,25(18):134-135.
[2]王守堂,赵仁,韩仁见.康复新液治疗消化性溃疡50例临床观察[J].中国社区医师,2015,31(1):104-105.
[3]徐宝琪.泮托拉唑治疗消化性溃疡的疗效及安全性[J].包头医学院学报,2016,32(1):57-58.
[4]刘辽,杨代喜,蒋丹,等.康复新液联合泮托拉唑治疗消化性溃疡疗效及安全性的系统评价[J].中成药,2014,34(3):491-497.
[5]谢福珍.康复新液治疗难治性消化性溃疡临床疗效观察[J].心血管病防治知识(学术版),2014,23(4):151-152.
[6]陈新孚.康复新液联合泮托拉唑治疗消化性溃疡疗效观察及安全性评价[J].临床合理用药杂志,2016,9(26):54-55.
[7]何颖.康复新液联合泮托拉唑治疗消化性溃疡疗效及安全性的研究[J].大家健康,2016,10(8):163-164.
[8]孙楹.康复新液联合泮托拉唑治疗消化性溃疡的疗效及安全性[J].临床合理用药杂志,2017,10(5):41-42.
[9]马晨飞.康复新液联合泮托拉唑三联疗法治疗消化性溃疡的临床疗效[J].临床合理用药杂志,2016,21(6):69-70.
[10]张海定,裘亚龙,卓维波.康复新液联合三联疗法治疗幽门螺杆菌相关十二指肠球部溃疡临床研究[J].新中医,2016,8(13):81-83.
[11]何敏.康复新液与泮托拉唑结合用于消化性溃疡治疗疗效及安全性评价[J].中国社区医师,2016,20(17):100-101.
[12]曹静,李长生.消化性溃疡行康复新液联合雷贝拉唑三联疗法的疗效及对炎性因子和血液流变学的影响[J].现代消化及介入诊疗,2016,2(12):217-219.
[2]王守堂,赵仁,韩仁见.康复新液治疗消化性溃疡50例临床观察[J].中国社区医师,2015,31(1):104-105.
[3]徐宝琪.泮托拉唑治疗消化性溃疡的疗效及安全性[J].包头医学院学报,2016,32(1):57-58.
[4]刘辽,杨代喜,蒋丹,等.康复新液联合泮托拉唑治疗消化性溃疡疗效及安全性的系统评价[J].中成药,2014,34(3):491-497.
[5]谢福珍.康复新液治疗难治性消化性溃疡临床疗效观察[J].心血管病防治知识(学术版),2014,23(4):151-152.
[6]陈新孚.康复新液联合泮托拉唑治疗消化性溃疡疗效观察及安全性评价[J].临床合理用药杂志,2016,9(26):54-55.
[7]何颖.康复新液联合泮托拉唑治疗消化性溃疡疗效及安全性的研究[J].大家健康,2016,10(8):163-164.
[8]孙楹.康复新液联合泮托拉唑治疗消化性溃疡的疗效及安全性[J].临床合理用药杂志,2017,10(5):41-42.
[9]马晨飞.康复新液联合泮托拉唑三联疗法治疗消化性溃疡的临床疗效[J].临床合理用药杂志,2016,21(6):69-70.
[10]张海定,裘亚龙,卓维波.康复新液联合三联疗法治疗幽门螺杆菌相关十二指肠球部溃疡临床研究[J].新中医,2016,8(13):81-83.
[11]何敏.康复新液与泮托拉唑结合用于消化性溃疡治疗疗效及安全性评价[J].中国社区医师,2016,20(17):100-101.
[12]曹静,李长生.消化性溃疡行康复新液联合雷贝拉唑三联疗法的疗效及对炎性因子和血液流变学的影响[J].现代消化及介入诊疗,2016,2(12):217-219.